Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ono Pharmaceutical Co. Ltd.

www.ono.co.jp

Latest From Ono Pharmaceutical Co. Ltd.

BMS’s Opdivo On Track For Esophageal Cancer Indication

Opdivo showed a 23% fall in the risk of death and 2.5-month improvement in median overall survival compared to chemotherapy in Phase III esophageal cancer trial.

ImmunoOncology Clinical Trials

Elevar Aims For Rivoceranib Turnaround After Positive Phase III Update

Despite failing to meet the primary endpoint in recent top-line Phase III results, Elevar Therapeutics (formerly LSK BioPharma) is hopeful that rivoceranib still has potential in late-stage gastric cancer based on generally positive full efficacy data from the global Phase III study presented at ESMO.

Clinical Trials Cancer

Approval Positions Roxadustat As Japan HIF-PHI Pioneer

The latest batch of product approvals in Japan positions Astellas’s roxadustat as the pioneer in the country’s potentially large HIF-PH inhibitor market in anemia, while Takeda and Meiji Seika see other important approvals and the first biosimilar teriparatide receives a nod.

Japan Approvals

Finance Watch: Nkarta, Passage Bio Raise Venture Capital Mega-Rounds

Private Company Edition: Nkarta, Passage Bio and Achilles kicked off September with VC deals totaling more than $100m each. Also, Repare raised $82.5m and SutroVax won CARB-X cash.

Financing ImmunoOncology
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Ono Pharmaceutical Co. Ltd.
  • Senior Management
  • Gyo Sagara, Pres. & CEO
    Isao Ono, Dir., Corp. Research
  • Contact Info
  • Ono Pharmaceutical Co. Ltd.
    Phone: (81) 6 6263 5670
    8-2 Kyutaromachi 1-Chome
    Chuo-ku
    Osaka, 541-8564
    Japan
Advertisement
Advertisement
UsernamePublicRestriction

Register